Rhythm Pharmaceuticals (RYTM) Long-Term Investments (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Long-Term Investments of $2.5 million for Q1 2026, down 64.75% year-over-year from $7.1 million in Q1 2025, and down 23.37% quarter-over-quarter from $3.3 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Long-Term Investments (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Long-Term Investments for 6 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 64.75% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (down 64.75% YoY), while the FY2025 annual figure was $3.3 million, down 55.15% from the prior year.
- Long-Term Investments fell to $2.5 million in Q1 2026 per RYTM's latest filing, from $3.3 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $18.4 million in Q1 2022 and bottomed at $2.2 million in Q2 2025.
- Historically, Long-Term Investments has averaged $11.3 million across 5 years, with a median of $13.8 million in 2024.
- Annual changes were most pronounced in 2022 — Long-Term Investments jumped 48.26% — and 2025, when it slumped 82.59%.
- Rhythm Pharmaceuticals' Long-Term Investments stood at $16.7 million in 2022, then decreased by 9.94% to $15.0 million in 2023, then sank by 51.16% to $7.3 million in 2024, then slumped by 55.15% to $3.3 million in 2025, then retreated by 23.37% to $2.5 million in 2026.
- Business Quant data shows RYTM's Long-Term Investments at $2.5 million in Q1 2026, $3.3 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 2.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.29 Mn |
| Mar 31, 2026 | 2.52 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 2.22 Mn |
| Mar 31, 2025 | 7.14 Mn |
| Dec 31, 2024 | 7.33 Mn |
| Sep 30, 2024 | 11.99 Mn |
| Jun 30, 2024 | 12.75 Mn |
| Mar 31, 2024 | 13.80 Mn |
| Dec 31, 2023 | 15.00 Mn |
| Sep 30, 2023 | 15.00 Mn |
| Jun 30, 2023 | 15.52 Mn |
| Mar 31, 2023 | 16.75 Mn |
| Dec 31, 2022 | 16.66 Mn |
| Sep 30, 2022 | 15.62 Mn |
| Jun 30, 2022 | 15.79 Mn |
| Mar 31, 2022 | 18.36 Mn |
| Dec 31, 2021 | 11.82 Mn |
| Sep 30, 2021 | 10.53 Mn |